DocMorris wins first round in German case

18 December 2006

The Netherlands direct-mail and Internet pharmacy group DocMorris.com has cleared a further hurdle in its contest with the German state authorities in the Saarland district over its right to operate a pharmacy in Saarbruecken.

A court in the city has now ruled in favor of DocMorris. com saying - according to the company - that it can see no reason in civil law to vary the current permission to operate the business. The company's pharmacy subsidiary in Saarbruecken will however remain closed until a further bridge in the legal process has been crossed. Last summer, a lower court rejected the complaint of a German pharmacist that a foreign-owned pharmacy could not legally operate inside Germany.

Nevertheless, a number of legal experts say the acquisition of the pharmacy by DocMorris.com breaches current pharmacy law. While a foreign pharmacist may run a pharmacy in Germany, this does not extend to the establishment as in the DocMorris.com case of a limited company. The German federal association of pharmacists issued a criminal complaint against DocMorris.com as far back as 2002 (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight